Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADELOS: Osimertinib in T790M+ NSCLC
NCT02997501Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2016
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Dec 2016; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02997501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02997501.